Abstract 851P
Background
Acute myeloid leukemia (AML) is a clonal malignancy of the stem cell precursors of the myeloid lineage associate with uncontrolled proliferation and impaired differentiation of hematopoietic stem cells. Among the different genes found amplified in AML, the oncogene MYC is one of the prognostic factors with an impact of AML. Albeit MYC is a well know factor associated with the uncontrolled proliferation of AML, the mechanism that led to the oncogenesis established by MYC are not well known. Zebrafish has recently emerged as a valid model organism to study cancer development because of its genetic accessibility.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we proceeded with FACS analysis of adult whole kidney marrow (WKM) of lyz:hMYC fish. Immunohistochemical analysis (IHC) of whole zebrafish was made to check the infiltration of cells and possible metastasis. May-Grunwald stain was made to check the kidney marrow population. Gene expression profile of WKM was performed to check the expression of genes associated with myc and its patthway. We conducted a Metagenomic analysis on possible variations in the intestinal microbiota associated with the disease causing its progression.
Results
FACS analysis of lyz:hMYC zebrafish revealed the expansion of myeloid cells with a significant reduction of erythroid cells, associated with anemia. The IHC analysis of whole lyz:hMYC zebrafish showed infiltration of myeloid cells into different organs confirming that those cells can proliferate unconditionally and metastasise. May-Grunwald analysis showed a higher number of blast cells unable to differentiate towards mature granulocytes in lyz:hMYC zebrafish than in their wild type siblings. The gene expression profile of WKM demonstrated the overexpression of exogenous MYC and of endogenous myc, suggesting a positive auto-regulation of MYC. Metagenomic analysis revealed that the gut microbes of AML fish were significantly altered with the possibility to be associated the progression of AML.
Conclusions
The model developed here is an excellent tool to further understand the mechanisms involved in MYC-induced AML and the relevance of gut microbiota on this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18